Immune cell therapy shows promise for rare Muscle-Weakening disease
Disease control
Ongoing
This early-phase study tests a new treatment called CABA-201 for people with generalized myasthenia gravis, a condition that causes muscle weakness. The therapy uses a patient's own immune cells, modified to target and destroy faulty immune cells that attack the body. The main go…
Phase: PHASE1, PHASE2 • Sponsor: Cabaletta Bio • Aim: Disease control
Last updated May 11, 2026 20:49 UTC